Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose by Maki, Kevin C et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Nutrition Journal
Open Access Research
Indices of insulin sensitivity and secretion from a standard liquid 
meal test in subjects with type 2 diabetes, impaired or normal 
fasting glucose
Kevin C Maki*1, James M McKenney2, Mildred V Farmer3, Matthew S Reeves1 
and Mary R Dicklin1
Address: 1Provident Clinical Research, Bloomington, IN, USA, 2National Clinical Research, Richmond, VA, USA and 3Meridien Research, St 
Petersburg, FL, USA
Email: Kevin C Maki* - kmaki@providentcrc.com; James M McKenney - JMcKenney@ncrinc.net; 
Mildred V Farmer - mfarmer@meridienresearch.net; Matthew S Reeves - mreeves@providentcrc.com; 
Mary R Dicklin - mdicklin@providentcrc.com
* Corresponding author    
Abstract
Background: To provide an initial evaluation of insulin sensitivity and secretion indices derived
from a standard liquid meal tolerance test protocol in subjects with normal (NFG), impaired fasting
glucose (IFG) or type 2 diabetes mellitus.
Methods: Areas under the curve (AUC) for glucose, insulin and C-peptide from pre-meal to 120
min after consumption of a liquid meal were calculated, as were homeostasis model assessments
of insulin resistance (HOMA2-IR) and the Matsuda index of insulin sensitivity.
Results: Subjects with NFG (n = 19), IFG (n = 19), and diabetes (n = 35) had mean ± SEM HOMA2-
IR values of 1.0 ± 0.1, 1.6 ± 0.2 and 2.5 ± 0.3 and Matsuda insulin sensitivity index values of 15.6 ±
2.0, 8.8 ± 1.2 and 6.0 ± 0.6, respectively. The log-transformed values for these variables were highly
correlated overall and within each fasting glucose category (r = -0.91 to -0.94, all p < 0.001). Values
for the product of the insulin/glucose AUC ratio and the Matsuda index, an indicator of the ability
of the pancreas to match insulin secretion to the degree of insulin resistance, were 995.6 ± 80.7
(NFG), 684.0 ± 57.3 (IFG) and 188.3 ± 16.1 (diabetes) and discriminated significantly between
fasting glucose categories (p < 0.001 for each comparison).
Conclusion: These results provide initial evidence to support the usefulness of a standard liquid
meal tolerance test for evaluation of insulin secretion and sensitivity in clinical and population
studies.
Background
Both impaired insulin sensitivity and pancreatic beta-cell
dysfunction play central roles in the pathogenesis of type
2 diabetes mellitus. Methods for assessment of these
parameters in research settings, including mathematical
modeling of data obtained during intravenous glucose
tolerance tests, as well as euglycemic and hyperglycemic
clamp procedures, have been evaluated extensively [1-3].
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However, the cost and sophistication of these methods
generally restrict their use to studies evaluating a limited
number of individuals.
A variety of methods of deriving surrogate measures of
insulin sensitivity and secretion from the oral glucose tol-
erance test have been evaluated. These have been shown
to perform reasonably well for discrimination between
groups and individuals with differing levels of insulin
resistance and beta-cell dysfunction [3-6]. Recently, Ret-
nakaran et al. [7] demonstrated a hyperbolic relationship
between the Matsuda index of insulin sensitivity and the
ratio of the total areas under the curve (AUC) for insulin
and glucose (AUCins/glu) over 120 min derived from oral
glucose tolerance tests in subjects with normal and
impaired glucose tolerance. This is similar to the hyper-
bolic relationship between the acute insulin response to
an intravenous glucose load and insulin sensitivity
derived from the minimal model that has been demon-
strated by Kahn et al. [8,9]. Thus, the product of these two
indices (Matsuda index * AUCins/glu) may be a useful tool
for assessing beta-cell function in relation to the level of
insulin sensitivity in population and clinical studies, anal-
ogous to the disposition index from the intravenous glu-
cose tolerance test with minimal model analysis (acute
insulin response * insulin sensitivity index).
In recent years, the roles of incretins released postprandi-
ally (e.g., glucagon like peptide-1 and gastric inhibitory
peptide) as modulators of glucose homeostasis and appe-
tite have become topics of intense interest [10-12]. Incre-
tin responses vary according to glucose tolerance status
and may differ depending on the nature of the stimulus.
For example, Vollmer et al. [12] found that the gastric
inhibitory peptide response to a mixed meal was 186%
larger than that elicited by an oral glucose load.
In addition, among individuals at increased risk for devel-
opment of diabetes, multiple metabolic and hemody-
namic disturbances (i.e., the cardiometabolic syndrome)
are often present. In clinical and epidemiological studies
it may therefore be of interest to assess not only determi-
nants of glucose homeostasis, but also other metabolic
variables such as postprandial lipid, lipoprotein and
incretin responses. Accordingly, the ability to assess insu-
lin sensitivity and secretion from a meal tolerance test has
substantial utility for epidemiologic and clinical research,
and has been evaluated in several studies [12-18]. How-
ever, the meals employed have typically utilized solid
foods, which may present problems regarding standardi-
zation across multiple research sites due to varying ingre-
dients used in food preparation from region to region and
country to country; differences in meal preparation meth-
ods; and subject-related elements such as the degree to
which foods are chewed. The aim of this investigation was
to provide an initial assessment of insulin sensitivity and
secretion indices using a widely available and easily stand-
ardized liquid meal tolerance test in subjects with normal
fasting glucose (NFG), impaired fasting glucose (IFG) or
type 2 diabetes.
Methods
The data for the present investigation are from tests com-
pleted for the control condition in a clinical trial. Data
were collected from three clinical research sites in the
United States under Good Clinical Practice Guidelines,
the Declaration of Helsinki (2000), and the US 21 Code
of Federal Regulations (Part 50 – Protection of Human
Subjects). An institutional review board (Schulman Asso-
ciates Institutional Review Board, Inc., Cincinnati, OH)
approved the protocol before the initiation of the study.
Informed consent was obtained from all subjects before
beginning any protocol-specific procedures. Subjects were
informed of their right to withdraw from the study at any
time.
Subjects
Men and non-pregnant, non-lactating women with and
without type 2 diabetes were enrolled. Eligible partici-
pants were each 18–74 y of age with body mass index <40
kg/m2. Subjects without diabetes were required to have no
history of glucose intolerance or signs or symptoms of
hypoglycemia and to have screening levels of glycosylated
hemoglobin (HbA1c) ≤6.0%, and fasting plasma glucose
<6.11 mmol/L. Subjects with diabetes had been diag-
nosed at least one year earlier and treated for at least 12
weeks with stable dose(s) of a sulfonylurea alone or with
a sulfonylurea plus metformin and/or a thiazolidinedi-
one, and had screening levels of HbA1c ≤9.0% and fasting
plasma glucose <11.1 mmol/L. Individuals with poorly
controlled hypertension or significant renal, pulmonary,
hepatic or biliary disease; a recent history of a cardiovas-
cular event; or any gastrointestinal condition that could
potentially interfere with absorption of the study product
were excluded. The use of selected medications within
eight weeks of the initiation of screening procedures was
not allowed, including insulin, meglitinides, alpha-glu-
cosidase inhibitor agent(s) and systemic corticosteroids.
Test Meals
Subjects received standard meal tolerance tests (active and
control) on different days ~1 week apart in a crossover
design. Only data from the control test are presented. Sub-
jects were instructed to consume a diet containing at least
150 g/d of carbohydrate and to avoid vigorous physical
activity during the 48 h prior to the meal test, confirmed
by queries when subjects arrived for testing after fasting
for at least 10 hours. Subjects consumed half of a 502 g,
500 kcal chocolate flavored shake (Ensure®, Abbott Nutri-
tion, Abbott Laboratories, Columbus, OH), ingested twoNutrition Journal 2009, 8:22 http://www.nutritionj.com/content/8/1/22
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placebo capsules, and then consumed the second half of
the shake over a 10 min period. The shake contained 80 g
carbohydrate, 12 g fat, and 18 g protein. Any medications
normally taken by the subject in the morning were admin-
istered 20 min prior to the start of the test meal.
Blood Pressure
Using an automatic blood pressure monitor (Vital Signs
Monitor 300 Series, Welch Allyn®, Beaverton, OR), dupli-
cate systolic and diastolic blood pressures were measured
after at least 5 min of seated rest and the two values aver-
aged.
Laboratory Measurements
Blood samples were collected from an indwelling catheter
for an assessment of the fasting lipid profile and measure-
ments of glucose, insulin and C-peptide pre-meal (average
of two values at times = -5 and 0 min) and 30, 60, 90, 120,
150, 180, 210, and 240 min after the beginning of test
meal consumption. Samples were drawn into chilled,
heparinized tubes and centrifuged rapidly to avoid glyco-
lysis. Biochemical measurements were completed by
Medpace Reference Laboratory (Cincinnati, OH). Plasma
glucose was measured by photometry following a hexoki-
nase reaction [19]. Plasma insulin [20] and C-peptide [21]
were analyzed using electrochemiluminescence immu-
noassays.
Statistical Analyses
Statistical analyses were generated using SAS version 9.1.3
or Statview version 5.0 (SAS Institute, Cary, NC). All tests
of statistical significance were completed at the 5% level.
The analysis dataset included all subjects who completed
a control test and had complete data for glucose and insu-
lin values pre-test and for the first 120 min post-meal.
Total AUCs for glucose, insulin and C-peptide from pre-
meal to 120 min were calculated using the trapezoidal
rule [22]. Homeostasis model assessments of insulin
resistance (HOMA2-IR) and pancreatic beta-cell function
(HOMA2-%B) were completed using the HOMA Calcula-
tor version 2.2.2 (http://www.dtu.ox.ac.uk, accessed July
2008). The Matsuda index of insulin sensitivity was calcu-
lated as follows, with glucose and insulin values in mmol/
L and pmol/L, respectively [4]:
where G0 and I0 are pre-meal values for insulin and glu-
cose and Gm and Im are mean post-meal values during the
first 120 min of the liquid meal tolerance test. The indices
evaluated were selected a priori based on their perform-
ance in previous investigations [7,13], and the timepoints
measured (0–120 min) were utilized because they are
anticipated to have the greatest utility in large-scale popu-
lation and multi-center clinical trials when a relatively
short test is desirable.
Subjects without diabetes were categorized as having NFG
if the average of their pre-meal plasma glucose values was
<5.56 mmol/L or IFG if this average was ≥ 5.56 mmol/L
[23]. Characteristics of the study participants according to
fasting glucose tolerance categories (NFG, IFG, diabetes)
were compared for continuous variables using analysis of
variance, followed by the Scheffé test for pairwise compar-
isons. For categorical variables, chi-square tests were
employed for comparisons between the three glucose tol-
erance categories and for pairwise comparisons between
categories where the overall chi-square test showed statis-
tical significance. Linear and non-linear regression analy-
ses were used to evaluate relationships between indicators
of insulin secretion and sensitivity.
Results
Subjects
Table 1 shows characteristics of the study sample, catego-
rized by fasting glucose tolerance status, which included
73 subjects, 19 each with NFG and IFG and 35 with dia-
betes. Of the subjects with diabetes, 9 were using a sulfo-
nylurea only, 16 were using a sulfonylurea plus
metformin, 4 were using a sulfonylurea plus a thiazolid-
inedione and 6 were using all three classes of medication.
The percentage of male subjects did not differ significantly
for those with NFG (26.3%) and IFG (47.4%), but was
higher for subjects with diabetes (80.0%) than in the
other two fasting glucose tolerance categories. The per-
centage of subjects who were non-Hispanic white (83–
84%) was similar, and not significantly different, in the
three fasting glucose tolerance groups. Mean age was sim-
ilar between those with NFG and IFG, but higher in sub-
jects with diabetes. Body mass index was highest among
subjects with diabetes, intermediate among those with
IFG and lowest in subjects with NFG. Total and low-den-
sity lipoprotein cholesterol concentrations did not differ
across categories, but high-density lipoprotein cholesterol
was significantly lower in those with diabetes than in the
other two groups. Mean fasting triglycerides and systolic
blood pressure were significantly higher among subjects
with diabetes compared with the NFG group, despite the
fact that a greater percentage of subjects with diabetes
were taking antihypertensive medication (4.3%, 18.2%
and 59.0% in the NFG, IFG and diabetes groups, respec-
tively). Diastolic blood pressure did not differ across fast-
ing glucose tolerance categories. Mean glycosylated
hemoglobin levels were in the normal range for subjects
with NFG and IFG and <7.0% for those with diabetes,
consistent with good glycemic control for a majority of
the subjects with diabetes.
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Fasting and Post-Meal Indices of Carbohydrate 
Metabolism
Glucose and insulin responses during the standard liquid
meal tolerance test among subjects in the three fasting glu-
cose tolerance categories are shown in Figures 1 and 2. The
AUC for glucose during the first 120 min of the test
increased progressively from NFG to IFG to diabetes. Peak
glucose and insulin responses occurred in the first 60 min
among subjects with NFG and IFG, but at 120 min among
subjects with diabetes. The AUC for insulin and C-peptide
were numerically higher among subjects with IFG than
among those with NFG, although the differences did not
reach statistical significance. Subjects with diabetes had
insulin and C-peptide responses that were intermediate
between the NFG and IFG groups.
Insulin Resistance
Insulin resistance, as indicated by the HOMA2-IR index or
the inverse of the Matsuda insulin sensitivity index, was
greatest among those with diabetes, intermediate among
those with IFG and lowest among those with NFG. The
difference between the diabetes and NFG groups was sta-
tistically significant by both measures (Table 1). Only the
HOMA2-IR index differed significantly between subjects
with IFG and diabetes, whereas only the Matsuda index
differed between subjects with NFG and IFG.
Beta-Cell Function
Surprisingly, the HOMA2-%B value did not differ signifi-
cantly across fasting glucose tolerance categories (Table
1). In contrast, the product of the AUCins/glu and the Mat-
suda index showed highly significant differences for all
comparisons (Figure 3). Compared to the mean value of
995.6 ± 80.7 in the NFG group, those with IFG showed a
value that was 31% lower and those with diabetes had a
mean value that was 81% lower.
Correlations between Measures of Insulin Resistance and 
Beta-Cell Function
Table 2 shows Pearson correlation coefficients between
the various measures of insulin resistance (or sensitivity)
and beta-cell function. Natural logarithmic transforma-
tions improved the fit for some variables. The Matsuda
index was strongly inversely correlated with HOMA2-IR,
overall and in all three fasting glucose tolerance groups,
with correlation coefficients of -0.914 to -0.942.
The Matsuda index and the HOMA2-IR index each
showed similar strengths of correlation with AUCins/glu
within all three groups (r values of ± 0.684 to ± 0.791).
The Matsuda index was much more strongly inversely cor-
related with HOMA2-%B in those with NFG (r = -0.935)
and IFG (r = -0.826) than in those with diabetes (r = -
Table 1: Characteristics of study subjects categorized by fasting glucose tolerance status
P-Values
Parameter NFG IFG Diabetes NFG vs. IFG NFG vs. Diabetes IFG vs. Diabetes
Total Number, M/F (n/n) 19 (5/14) 19 (9/10) 35 (28/7) 0.313 < 0.001 0.031
Age (years) 45.1 ± 4.2 45.7 ± 3.3 61.0 ± 2.0 0.989 <0.001 0.002
BMI (kg/m2) 25.8 ± 1.0 29.3 ± 1.2 32.7 ± 0.7 0.071 < 0.001 0.045
Total cholesterol (mmol/L) 5.35 ± 0.39 5.17 ± 0.24 4.72 ± 0.17 0.903 0.202 0.437
LDL cholesterol (mmol/L) 3.19 ± 0.35 2.96 ± 0.18 2.69 ± 0.14 0.799 0.246 0.649
HDL cholesterol (mmol/L) 1.53 ± 0.09 1.44 ± 0.12 1.07 ± 0.05 0.758 < 0.001 0.005
Triglycerides (mmol/L) 1.38 ± 0.18 1.73 ± 0.27 2.29 ± 0.25 0.695 0.048 0.308
Systolic BP (mm Hg) 117.0 ± 3.4 122.6 ± 3.3 129.1 ± 2.3 0.484 0.015 0.284
Diastolic BP (mm Hg) 72.6 ± 1.9 78.2 ± 1.8 77.1 ± 1.6 0.165 0.214 0.918
Fasting glucose (mmol/L) 5.22 ± 0.05 5.87 ± 0.06 7.53 ± 0.29 0.249 < 0.001 < 0.001
Fasting insulin (pmol/L) 52.8 ± 6.0 82.0 ± 11.0 124.8 ± 13.9 0.373 < 0.001 0.068
Fasting C-peptide (nmol/L) 0.63 ± 0.05 0.89 ± 0.08 1.27 ± 0.08 0.110 < 0.001 0.004
HbA1C (%) 5.2 ± 0.1 5.2 ± 0.1 6.7 ± 0.1 0.907 < 0.001 < 0.001
Glucose AUC (h*mmol/L) 11.1 ± 0.5 14.1 ± 0.8 23.1 ± 0.8 0.059 < 0.001 < 0.001
Insulin AUC (h*pmol/L) 894 ± 121 1346 ± 180 922 ± 103 0.102 0.988 0.075
C-peptide AUC (h*nmol/L) 4.2 ± 0.3 5.6 ± 0.4 4.7 ± 0.3 0.032 0.531 0.162
AUCins/glu (pmol/mmol) 78.6 ± 8.8 95.5 ± 12.2 40.7 ± 4.4 0.398 0.003 < 0.001
HOMA2-IR 1.00 ± 0.11 1.57 ± 0.21 2.48 ± 0.26 0.346 < 0.001 0.037
HOMA2-%B 83.7 ± 5.9 89.5 ± 7.9 86.7 ± 10.6 0.936 0.976 0.981
Matsuda Index 15.6 ± 2.0 8.8 ± 1.2 6.0 ± 0.6 0.003 < 0.001 0.254
Values are mean ± SEM unless otherwise specified.
Abbreviations: AUC = area under the curve, AUCins/glu= ratio of the total areas under the curve for insulin and glucose, BMI = body mass index, BP 
= blood pressure, HbA1c = glycosylated hemoglobin, HDL = high-density lipoprotein, HOMA2-IR = homeostasis model assessment of insulin 
resistance, HOMA2-%B = homeostasis model assessment of pancreatic beta-cell function, IFG = impaired fasting glucose, LDL = low-density 
lipoprotein, M/F = male/female, NFG = normal fasting glucose, Diabetes = type 2 diabetes mellitusNutrition Journal 2009, 8:22 http://www.nutritionj.com/content/8/1/22
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0.338). Similarly, HOMA2-IR was strongly correlated with
HOMA2-%B in the NFG (r = 0.959) and IFG (r = 0.946)
groups, but the correlation was less strong for those with
diabetes (r = 0.491).
Relationship between Insulin Secretion and Sensitivity
The relationship between insulin secretion and insulin
sensitivity can be expressed as insulin secretion = con-
stant/insulin sensitivity [7-9]. The pattern observed is con-
sistent with the expectation that declining glucose
tolerance would be associated with shifts to the left and
downward (Figure 4). However, it would also be expected
that the regression lines would have exponent values
equal to approximately -1.0 [equivalent to a slope of -1.0
in the equation loge AUCins/glu = intercept * slope (loge
Matsuda index)]. The slopes were all significantly differ-
ent from zero, but were also significantly different from -
1.0: NFG slope = -0.652 (95% CI -0.910 to -0.394), IFG
slope = -0.548 (95% CI -0.784 to -0.313), diabetes slope
= -0.734 (95% CI -0.967 to -0.502).
Discussion
This investigation provides preliminary evidence suggest-
ing that a standard liquid meal tolerance test may be used
to assess indices of insulin sensitivity and secretion across
the spectrum of glucose tolerance. The results conformed
to the expected relationships between insulin secretion
and sensitivity, as indicated by the AUCins/glu and the Mat-
suda index, respectively. The product of these two indices,
which is analogous to the disposition index (acute insulin
response * insulin sensitivity index) described by Kahn et
al. [8,9] was able to discriminate between the three cate-
gories of fasting glucose tolerance, even with relatively
small numbers of subjects. This product may therefore
provide a useful measure of the ability of the pancreas to
match insulin secretion to the prevailing degree of insulin
resistance.
Intravenous glucose tolerance tests and glycemic clamp
procedures are not practical for many clinical and epide-
miologic investigations because of the cost and high level
of sophistication required to conduct such tests. The oral
glucose tolerance test provides a possible alternative for
use in such instances. However, a meal tolerance test has
a number of potential advantages compared to the oral
glucose tolerance test. Because insulin resistant states are
associated not only with disturbances in carbohydrate
metabolism, but also with fasting and postprandial lipid
levels, it may be desirable to simultaneously assess post-
load glucose and lipid responses, without the need for
tests on separate days. A mixed meal tolerance test also
provides a more physiologic stimulus for assessing incre-
tin responses [12]. Some subjects experience nausea or
reactive hypoglycemia after a load consisting of glucose
only. Neither of these issues was experienced by any of the
73 subjects in our sample, although subjects with a history
of signs or symptoms of hypoglycemia were excluded
from participation. In addition, the liquid meal used in
Mean ± SEM plasma glucose values by timepoint during a standard liquid meal tolerance test according to fasting glucose toler- ance status Figure 1
Mean ± SEM plasma glucose values by timepoint during a standard liquid meal tolerance test according to fast-










































DiabetesNutrition Journal 2009, 8:22 http://www.nutritionj.com/content/8/1/22
Page 6 of 10
(page number not for citation purposes)
our study is a commercially available product that is easily
reproducible and requires no food preparation, thus can
be employed easily in a standardized fashion across mul-
tiple research sites.
Other investigators have studied liquid or solid mixed
meal loads for assessing insulin secretion or sensitivity
[12-18]. In particular, Aloulou and colleagues [13] evalu-
ated the ability to estimate insulin sensitivity using a
standard breakfast test with various methods, most of
which were originally validated using oral glucose toler-
ance test data. Using the minimal model-derived insulin
sensitivity index from intravenous glucose tolerance test
results as their standard for comparison, they found that
the Matsuda index was the strongest correlate of insulin
sensitivity (r = 0.656, p < 0.001). Retnakaran et al. [7] also
recently reported that the product of the Matsuda index
and the AUCins/glu was the best indicator of the appropri-
ateness of insulin secretion for the level of insulin sensitiv-
ity among several measures they evaluated. These findings
prompted the authors to select the Matsuda index and the
AUCins/glu  as the two measures for evaluation in the
present study. In addition, these indices can be easily cal-
culated using a spreadsheet, without the need for sophis-
ticated mathematical modeling software. The liquid test
meal used in the present investigation was similar to those
employed previously in studies of insulin secretagogue
medications [15,24].
The current study did not have gold standard indices of
insulin secretion or sensitivity against which to compare
the liquid meal tolerance test derived indices. The strong
inverse correlations between the HOMA2-IR and Matsuda
indices in all three fasting glucose tolerance groups (r = -
0.914 to -0.940) suggest that both are measuring the same
underlying physiologic process. Means for both indices
showed the expected order, in that subjects with diabetes
had the greatest degree of insulin resistance, subjects with
NFG had the least, and subjects with IFG had intermediate
values. Some caution is warranted regarding the correla-
tion between these measures because the HOMA2-IR
value is based on the product of fasting insulin and glu-
cose levels, whereas the Matsuda index contains this prod-
uct as an element of the calculation. However, both have
also been shown to correlate well with minimal model
and euglycemic clamp assessments of insulin sensitivity
[4,25].
Using a minimal model analysis of data from meal toler-
ance tests, Steil et al. [18] showed that the insulin sensitiv-
ity index from a meal tolerance test correlated with that
from a euglycemic clamp (r = 0.760, p < 0.001) to a degree
similar to that derived from an intravenous glucose toler-
ance test (r = 0.717, p = 0.001), but that the index derived
from the meal tolerance test was consistently higher than
that from the intravenous glucose tolerance test by a factor
of ~2.3. These results are in agreement with those from
Caumo and colleagues [14] who also found a strong cor-
relation between insulin sensitivity indices derived from
Mean ± SEM plasma insulin values by timepoint during a standard liquid meal tolerance test according to fasting glucose toler- ance status Figure 2
Mean ± SEM plasma insulin values by timepoint during a standard liquid meal tolerance test according to fast-
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minimal model analyses of meal and intravenous glucose
tolerance tests, but with 2.2-fold higher values from the
meal tolerance test (Spearman r = 0.89, p < 0.01). Thus,
the available data suggest that a meal tolerance test (liquid
or solid) can provide an appropriate stimulus for assess-
ing insulin sensitivity, although absolute values from such
tests may not be directly comparable to those derived
from the euglycemic clamp or intravenous glucose toler-
ance test.
The authors were surprised that HOMA2-%B did not dis-
criminate between the three fasting glucose tolerance
groups. The subjects with diabetes generally had good gly-
cemic control as indicated by an average HbA1c concentra-
tion <7.0% and were all taking sulfonylureas, which may
have contributed to higher values than might have been
the case otherwise. However, very similar values were
present in subjects with diabetes, IFG and NFG. In con-
trast, AUCins/glu did discriminate between diabetes and the
other categories, although not between the NFG and IFG
subjects. The product of the Matsuda index and AUCins/glu
discriminated between all three groups, consistent with
the view that greater insulin secretion was partially com-
pensating for the somewhat higher level of insulin resist-
ance present in the subjects with IFG, and underlining the
fact that the appropriateness of the pancreatic beta-cell
Results for the product of the Matsuda index of insulin sensitivity and the ratio of the areas under the curve for insulin to glu- cose over 120 min (AUC ins/glu) according to fasting glucose tolerance status Figure 3
Results for the product of the Matsuda index of insulin sensitivity and the ratio of the areas under the curve for 
insulin to glucose over 120 min (AUC ins/glu) according to fasting glucose tolerance status. NFG = normal fasting 










































All Comparisons P < 0.001
Table 2: Pearson correlation coefficients showing the 
relationships between indices of glucose homeostasis according 
to fasting glucose tolerance status
Loge HOMA2-IR LogeAUCins/glu HOMA2-%B
Normal Fasting Glucose
Loge Matsuda Index -0.940† -0.791† -0.935†
Loge HOMA2-IR 1.000 0.684† 0.959†
Loge AUCins/glu -- 1.000 0.699†
Impaired Fasting Glucose
Loge Matsuda Index -0.917† -0.766† -0.826†
Loge HOMA2-IR 1.000 0.741† 0.946†
Loge AUCins/glu -- 1.000 0.789†
Type 2 Diabetes Mellitus
Loge Matsuda Index -0.914† -0.745† -0.338*
Loge HOMA2-IR 1.000 0.717† 0.491†
Loge AUCins/glu -- 1.000 0.631†
All Subjects
Loge Matsuda Index -0.942† -0.237* -0.418†
Loge HOMA2-IR 1.000 0.185 0.520†
Loge AUCins/glu -- 1.000 0.511†
*P < 0.05; † P < 0.01
Abbreviations: AUCins/glu= ratio of the total areas under the curve for 
insulin and glucose, HOMA2-IR = homeostasis model assessment of 
insulin resistance, HOMA2-%B = homeostasis model assessment of 
pancreatic beta-cell functionNutrition Journal 2009, 8:22 http://www.nutritionj.com/content/8/1/22
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insulin response can only be interpreted in relation to the
prevailing degree of insulin resistance. Recently, Festa and
colleagues [26] reported that HOMA-%B underestimated
the degree of beta-cell dysfunction in subjects with
impaired glucose tolerance and early-stage, asymptomatic
type 2 diabetes, thereby supporting our results and con-
firming that post-load measures of beta-cell function are
more sensitive indicators of beta-cell dysfunction than
those derived from fasting values.
The relationship between insulin sensitivity (Matsuda
index) and insulin secretion (AUCins/glu) in the present
study was consistent with the expectation that progressive
worsening of glucose tolerance status from NFG to IFG to
diabetes would be associated with shifts downward and to
the left in the regression curves. However, slope of the
regression line for the equation loge AUCins/glu = intercept
* slope (loge Matsuda index) did not approximate -1.0 in
any of the three fasting glucose tolerance groups, as would
be expected based on results for the oral glucose tolerance
test described by Retnakaran et al. [7]. Values for the slope
of this regression line ranged from -0.734 to -0.548. The
reason for this difference between our results from liquid
meal tolerance tests and theirs from oral glucose tolerance
tests is unclear and will need to be investigated further. As
discussed above, findings from other investigators have
suggested that insulin sensitivity indices from mixed meal
tests correlate with those from methods that use an iso-
lated glucose stimulus, but are not always directly compa-
rable in absolute terms. One potential explanation for the
apparent difference is that differences in incretin
responses elicited by a mixed meal, compared with an oral
or intravenous glucose stimulus, alter the Matsuda index
to AUCins/glu relationship [12].
The present investigation was intended as an initial evalu-
ation of particular measures of insulin secretion (AUCins/
glu) and sensitivity (Matsuda index) derived from a stand-
ard liquid meal tolerance test. The results are encouraging,
but should be considered only a first step. Additional
studies will be needed to compare this approach directly
to established methods such as minimal model analyses,
as well as euglycemic and hyperglycemic clamp methods
for assessing insulin sensitivity and secretion. Moreover,
studies will be required to assess the test-retest coefficient
of variation in order to facilitate sample size calculations
for clinical intervention trials. While it can be argued that
the use of systemic insulin concentration as a surrogate
marker of beta-cell function was flawed because it reflects
both pancreatic secretion and hepatic extraction, the
Regression lines illustrating the relationships between the Matsuda index of insulin sensitivity and the ratio of the areas under  the curve for insulin to glucose over 120 min (AUC ins/glu in pmol/mmol) according to fasting glucose tolerance status Figure 4
Regression lines illustrating the relationships between the Matsuda index of insulin sensitivity and the ratio of 
the areas under the curve for insulin to glucose over 120 min (AUC ins/glu in pmol/mmol) according to fasting 
glucose tolerance status. NFG = normal fasting glucose (Y = 380.365*X-0.652); IFG = impaired fasting glucose (Y = 
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objective of this trial was to assess the utility of methods
previously evaluated using oral glucose or mixed solid
meal tolerance test data, but substituting a mixed liquid
meal as the stimulus. Those previous examinations col-
lected pre- and post-load insulin and glucose data, and we
followed the same approach.
Some additional limitations of the present study should
also be considered. The sample was relatively small and
selected for participation in a clinical trial. Subjects with
diabetes had good average glycemic control and were all
taking sulfonylurea medications. The subjects with IFG
did not cover the full range of fasting glucose levels for
this category due to the exclusion criteria established for
participation in the trial. Because no oral glucose toler-
ance test was completed, it was not possible to categorize
glucose tolerance in subjects without diabetes beyond the
classifications of NFG and IFG. Several investigators have
shown that subsets of subjects with pre-diabetes such as
those with isolated IFG, isolated impaired glucose toler-
ance, or both, differ regarding the degree to which periph-
eral insulin resistance, hepatic insulin resistance and beta-
cell dysfunction contribute to their type and degree of glu-
cose intolerance [3,27-29]. In the present study, some of
the subjects with NFG and IFG might have been shown to
have impaired glucose tolerance if oral glucose tolerance
test results had been available. Therefore, testing in a
broader sample across the entire spectrum of fasting and
post-load glucose tolerance will be needed to demonstrate
the generalizability of our results. Simultaneous measure-
ment of incretins and parameters related to lipid metabo-
lism would help to establish the utility of the standard
liquid meal tolerance test for evaluation of multiple met-
abolic responses.
Conclusion
In conclusion, the results from the present study suggest
that the standard liquid meal tolerance test may be a use-
ful alternative for assessment of insulin secretion and sen-
sitivity in clinical and population studies. Additional
research is warranted to further evaluate the validity and
reliability of this test for use in such settings.
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